PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing hernia devices for hernia repair and tissue reinforcement products; NovoSorb Dermal Beta Cell Implant to host pancreatic islets in the skin; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
P/B ratio for PolyNovo Limited (PNV.AX)
P/B ratio as of 2024: 22.30
According to PolyNovo Limited's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 22.30. At the end of 2023 the company had a P/B ratio of 16.23.
P/B ratio history for PolyNovo Limited from 1999 to 2024
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2024 | 22.30 |
| 2023 | 16.23 |
| 2022 | 50.74 |
| 2021 | 83.42 |
| 2020 | 70.52 |
| 2019 | 38.42 |
| 2018 | 11.80 |
| 2017 | 10.91 |
| 2016 | 9.14 |
| 2015 | 4.99 |
| 2014 | 4.24 |
| 2013 | 3.97 |
| 2012 | 3.89 |
| 2011 | 2.92 |
| 2010 | 2.10 |
| 2009 | 1.86 |
| 2008 | 1.65 |
| 2007 | 1.27 |
| 2006 | 1.03 |
| 2005 | 1.20 |
| 2004 | 1.17 |
| 2003 | 0.33 |
| 2002 | 0.16 |
| 2001 | 0.28 |
| 2000 | 0.15 |
| 1999 | 0.02 |